Literature DB >> 12889510

Genetic verification of the role of CCK-AR in pancreatic proliferation and blood glucose and insulin regulation using a congenic rat carrying CCK-AR null allele.

D H Moralejo1, T Ogino, H Kose, T Yamada, K Matsumoto.   

Abstract

A number of studies have indicated that cholecystokinin type A receptor (CCK-AR) plays a crucial role in postnatal pancreatic proliferation and blood glucose regulation through stimulating insulin secretion. The Otsuka Long-Evans Tokushima Fatty (OLETF) rat has been shown to possess poor pancreatic proliferation (PPP) capability after pancreatectomy (Px). Here we have constructed a congenic strain which introgressed an OLETF-derived 18.5 cM genomic fragment identified in our previous quantitative trait locus (QTL) analysis as a locus responsible for PPP into normoglycemic F344 genetic background The introgressed region includes CCK-AR null mutation. After Px, the congenic rat showed weak pancreatic proliferation equivalent to that of the OLETF rat. Furthermore, post-surgery non-fasting blood glucose levels for the congenic rats are significantly higher in comparison with the F344 rats. At 28 days after Px, the congenic rats also showed lower blood insulin levels than the F344 rats. These results further provide the genetic evidence that 1) CCK-AR is essential for pancreatic regeneration; 2) impaired pancreatic proliferation mediates the development of hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12889510

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  5 in total

1.  Suppression of transforming growth factor beta signalling aborts caerulein induced pancreatitis and eliminates restricted stimulation at high caerulein concentrations.

Authors:  Stefan Wildi; Jörg Kleeff; Julia Mayerle; Arthur Zimmermann; Erwin P Böttinger; Lalage Wakefield; Markus W Büchler; Helmut Friess; Murray Korc
Journal:  Gut       Date:  2006-11-29       Impact factor: 23.059

Review 2.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

Review 3.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.

Authors:  Erin E Cawston; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

4.  Normal feeding and body weight in Fischer 344 rats lacking the cholecystokinin-1 receptor gene.

Authors:  J E Blevins; J Overduin; J M Fuller; D E Cummings; K Matsumoto; D H Moralejo
Journal:  Brain Res       Date:  2008-12-16       Impact factor: 3.252

5.  Alterations in activity and energy expenditure contribute to lean phenotype in Fischer 344 rats lacking the cholecystokinin-1 receptor gene.

Authors:  James E Blevins; Daniel H Moralejo; Tami H Wolden-Hanson; Brendan S Thatcher; Jacqueline M Ho; Karl J Kaiyala; Kozo Matsumoto
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-10-31       Impact factor: 3.619

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.